trial

Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia

NCTId NCT06387771
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 20 (estimated)
Sponsored by Clinica Universidad de Navarra, Universidad de Navarra
Primary completion 2025-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-09-22
Primary completion
2025-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Tolcapone

Sponsors

Clinica Universidad de Navarra, Universidad de NavarraLead Sponsor

Investigators

1
Patricio Molero, MD, PhDPrincipal Investigator

Sites

1 total
Pamplona, Spain

Linked catalysts

1
Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia — primary completion2025-08

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE2
Primary Completion Date
2025-08
Status
UNKNOWN
relationships
The graph out of here
drug
Tolcapone
drug
lead_sponsor
Clinica Universidad de Navarra, Universidad de Navarra
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Patricio Molero, MD, PhD
person